Numerous studies have suggested the use of NHE inhibitors in the treatment of various types of cancer, such as breast or colon cancer (Miraglia et al., 2005; Rolver et al., 2020), however, clinical evaluation of NHE inhibitors is currently limited to cardiac disease, particularly in connection with ischemia-reperfusion injury, in which the cardioprotective effect of cariporide and eniporide was demonstrated in two clinical trials (Chaitman, 2003; Mentzer et al., 2008). This evidence concerns the gene SLC9C1 and colonic neoplasm.